Armata Pharmaceuticals, INC. 8-K Filing

FAQ

Key Financial Figures

• $0.01 — , shares of its common stock, par value $0.01 per share (the "Common Stock"), having
• $100,000,000 — ng an aggregate offering price of up to $100,000,000 (the "Placement Shares") subject to cer

Filing Documents

• tm2532031d2_8k.htm (8-K) — 30KB
• tm2532031d2_ex1-1.htm (EX-1.1) — 240KB
• tm2532031d2_ex5-1.htm (EX-5.1) — 8KB
• tm2532031d2_ex5-1img001.jpg (GRAPHIC) — 8KB
• 0001104659-25-117387.txt ( ) — 514KB
• armp-20251201.xsd (EX-101.SCH) — 3KB
• armp-20251201_lab.xml (EX-101.LAB) — 33KB
• armp-20251201_pre.xml (EX-101.PRE) — 22KB
• tm2532031d2_8k_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On December 1, 2025, Armata Pharmaceuticals, Inc. (the "Company") entered into a Capital on Demand Sales Agreement (the "Sales Agreement") with JonesTrading Institutional Services LLC ("Jones") with respect to an at the market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.01 per share (the "Common Stock"), having an aggregate offering price of up to $100,000,000 (the "Placement Shares") subject to certain conditions, through Jones as sales agent. The issuance and sale, if any, of the Placement Shares by the Company under the Sales Agreement will be made pursuant to the Company's effective registration statement on Form S-3 (File No. 333-289585) (the "Registration Statement") and the prospectus supplement dated December 1, 2025, and filed with the U.S. Securities and Exchange Commission (the "SEC") pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the "Securities Act"). Jones may sell the Placement Shares by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415(a)(4) of the Securities Act, including, without limitation, sales made on or through the NYSE American ("NYSE American") or any other existing trading market for the Common Stock. Subject to the terms of a placement notice, Jones may also sell Placement Shares by any other method permitted by law, including but not limited to in negotiated transactions, subject to the prior written consent of the Company. Jones will use commercially reasonable efforts consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of the NYSE American, to sell the Placement Shares from time to time, up to the amount specified in, and otherwise in accordance with the terms of the applicable placement notice. The Company will pay Jones a commission of up

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Capital on Demand Sales Agreement, dated as of December 1, 2025, by and between the Company and JonesTrading Institutional Services LLC. 5.1 Opinion of Ballard Spahr LLP. 23.1 Consent of Ballard Spahr LLP (included in Exhibit 5.1 above). 104 Cover Page Interactive Data File (embedded within Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 1, 2025 Armata Pharmaceuticals, Inc. By: /s/ David House Name: David House Title: Senior Vice President, Finance and Principal Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR